Anti-PARIS/ZNF746 Antibody (N196/12)

Catalog No.

RHN25701

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Zinc finger protein 746, PARIS, Parkin-interacting substrate, ZNF746

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

N196/12

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC., PMID:40511820

MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis., PMID:40504622

Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy., PMID:40502628

Germline-targeting HIV Envelope SOSIP immunization more frequently elicits broadly-neutralizing antibody precursor responses in infant compared to juvenile rhesus macaques., PMID:40501834

Implementing an assay detecting anti-drug antibody against emicizumab: experience from one center in France., PMID:40499914

Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation., PMID:40498433

French guidelines for the diagnostic and management of MOG antibody-associated disease., PMID:40494723

Predicting high-fitness viral protein variants with Bayesian active learning and biophysics., PMID:40489612

Novel pretransplant desensitization strategies in heart transplantation., PMID:40486117

A nationwide experience of biological treatments in children with eosinophilic esophagitis., PMID:40483369

Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control., PMID:40481031

TRANSFUSION STRATEGY AND ALLO-IMMUNIZATION TO RED BLOOD CELL ANTIGENS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PARTIAL DONOR/RECIPIENT RH MATCHING., PMID:40480293

Prevalence of treated hyper- and hypo-thyroidism and sociodemographic and geographic disparities in France in 2020., PMID:40478662

[New treatments for cutaneous lupus]., PMID:40476397

Advances in the treatment of ANCA-associated vasculitis., PMID:40473820

Role of malaria exposure and off-target responses on RTS,S/AS02A vaccine immunogenicity and protection in Mozambican children., PMID:40473700

Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies., PMID:40473271

mAb production kinetics in CHO batch culture: exploring extracellular and intracellular dynamics., PMID:40470507

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party., PMID:40467580

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417

Versatile tethering system to control cell-specific targeting of bioengineered extracellular vesicles., PMID:40461587

Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival., PMID:40461501

Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial., PMID:40460988

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade., PMID:40460830

Patritumab deruxtecan induces immunogenic cell death., PMID:40458967

Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)., PMID:40456838

Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report., PMID:40453263

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma., PMID:40453131

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study., PMID:40450573

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial., PMID:40450141

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study., PMID:40449498

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497

Targeting CD8+ T cells in cardiovascular diseases - current options and therapeutic perspectives., PMID:40448685

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351

Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773

Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration., PMID:40446030

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial., PMID:40441802

Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma., PMID:40440582

Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer., PMID:40440007

Lichenoid graft-versus-host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation., PMID:40439472

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue., PMID:40432141

Serological Correlate of Protection Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern., PMID:40432127

Cognitive Impairment in ANCA-Associated Vasculitis: A Cross-Sectional Pilot Study., PMID:40429578

Characteristics of SARS-CoV-2-associated severe episodes of monoclonal gammopathy-associated capillary leak syndrome (Clarkson disease)., PMID:40419837

Reverse-normal immunopurification: An effective approach for purifying recombinant erythropoietin from its analogues in doping analysis., PMID:40419139

Targeted fusion of antibody-secreting cells: Unlocking monoclonal antibody production with hybridoma technology., PMID:40418588

Mutations in RNU4ATAC Are Associated With Chilblain-Like Lesions and Enhanced Type I Interferon Signalling., PMID:40415209

Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC., PMID:40413561

Quantitative Pharmacology Methods for Bispecific T Cell Engagers., PMID:40413295

Document Download

Anti-PARIS/ZNF746 Antibody (N196/12).pdf